Lactobacillus paracasei F19 is an emerging probiotic strain that shows considerable promise for use in functional foods for intestinal health. In a multicentre European research project, human feeding trials provided an insight into the ability of this strain to survive gastric transit and transiently colonize the human intestinal tract. Analysis of the faecal microbiota in healthy human volunteers showed that a proportion of the subjects carried a strain indistinguishable from L. paracasei F19 naturally within their intestines. When consumed in different foods, L. paracasei F19 survived gastric transit in healthy infants, adults, and elderly subjects. The bacterium transiently colonized both the colonic lumen and mucosa. Molecular analysis of faecal and colonic biopsy samples from children fed the probiotic showed that L. paracasei F19 did not perturb the population dynamics of other major populations of bacteria in the intestinal microbiota. This strain was well tolerated by young children, healthy adults, adults with milk-hypersensitivity and elderly subjects infected with Helicobacter pylori.
INTRODUCTION
Probiotics are live microorganisms included in foods to provide health bene ts to consumers by positively contributing to the composition and activity of their intestinal microbiota (1) . A number of bacteria from the genera Lactobacillus and Bi dobacterium have been identi ed as having characteristics necessary for probiotic action. These properties include technological parameters, survival during passage through the upper gastrointestinal tract, transient persistence in the intestinal tract, and proven safety for human consumption (2) (3) (4) . Health bene ts to humans are strain speci c, with different probiotic organisms providing varying effects on health parameters such as immunomodulation and protection against intestinal infections (5) .
Lactobacillus paracasei ssp. paracasei isolate F19 (Lactobacillus F19) is an emerging probiotic strain that is readily amenable to commercial manufacture and which retains viability and functionality in dairy products while providing good avour and organoleptic properties (6) . This strain has shown considerable promise during in ×itro trials assessing its potential to survive gastric transit and to persist in the colonic environment (unpublished data). As part of a multicentre European project named PROB-DEMO (described in (7)), L. paracasei was included in human pilot studies to assess the ability of probiotics to survive intestinal transit and to examine their in uence on the native microbiota of consumers. Subjects in the trials were also monitored for any deleterious effects resulting from probiotic consumption. The current paper outlines the results of trials involving Lactobacillus F19, focusing on its survival, ecology and safety in the human intestinal tract.
HUMAN FEEDING STUDIES
Four pilot feeding studies assessing Lactobacillus F19 were conducted within the PROBDEMO project, involving volunteers from Finland and Sweden (Table I) . A variety of target groups were tested, ranging in age from infants to the elderly, and including both healthy subjects and individuals with mild health disorders. The probiotic delivery systems included capsules and milk containing freeze-dried Lactobacillus F19, and milk and yoghurt fermented by mesophilic or yoghurt cultures including Lactobacillus F19. In each case, samples of the product were tested to ensure delivery of viable and functionally active probiotic bacteria to the volunteers throughout the trials.
Pre×alence of Lactobacillus F19 in the nati×e intestinal microbiota of humans
The intestinal microbiota of humans is complex, containing more than 400 different species of bacteria and possibly many thousands of strains (8, 9) . Modern molecular techniques such as PCR and restriction fragment length polymorphism (RFLP) analysis allow researchers to identify individual strains within the intestinal microbiota. Lactobacillus F19 was originally isolated from the small intestine of a human subject. This strain was not produced commercially at the time of the trials described in this report, and therefore, the subjects were not previously exposed to this strain in probiotic foods. Despite this, strains indistinguishable from Lactobacillus F19 using RAPD (randomly ampli ed polymorphic DNA) analysis were identi ed in the initial baseline sample (pre-administration) of one of the individuals in Trial B, and in three samples from one individual in the control group in Trial D. Therefore, Lactobacillus F19, or at least very closely related strains, are present in the native intestinal microbiota of a small proportion of individuals from Nordic countries. This enables further con dence in the strain's safety and its ability to persist in the intestinal tract of humans.
Earlier research investigating the diversity of strains of lactobacilli and bi dobacteria within humans failed to nd common strains among 10 people, suggesting that individuals may harbour distinct populations of these bacteria within their intestinal tracts (10) . In contrast, the PRODEMO studies suggest that strains closely related to Lactobacillus F19 are present in the intestinal tract of a small percentage of the population in northern Europe.
Sur×i×al of Lactobacillus F19 in the human intestinal tract
If a probiotic bacterium is to bene cially contribute to the activity of the intestinal microbiota it must successfully survive transit through the harsh gastric environment, and then tolerate bile released into the small intestine that can also reduce bacterial viability. Trials conducted using a sophisticated in ×itro model of the intestinal tract at TNO in the Netherlands indicated that Lactobacillus F19 can be expected to survive intestinal transit (11) . In order to con rm intestinal transit survival in humans, analysis of faecal samples was conducted prior to and following probiotic ingestion. RAPD analysis using validated primers for the speci c detection of Lactobacillus F19 in intestinal samples was developed in order to identify this strain among the myriad of strains present in the intestinal microbiota. In each of the four trials described in Table I , faecal samples were cultured for total lactobacilli using Rogosa agar and then colonies resembling Lactobacillus F19 were analysed using RAPD to con rm their identity. In all of the age groups tested, from 1-year-old infants to subjects \ 85 years of age, Lactobacillus F19 could be identi ed in faecal samples following ingestion. During ingestion of the probiotic, Lactobacillus F19 was the numerically dominant Lactobacillus isolated in faecal samples (Table II) . This conrmed that Lactobacillus F19 survived intestinal transit and could transiently colonize the intestinal tract of humans. When monitoring of faecal microbiota was continued following cessation of probiotic consumption in Trials A and D, six infants were colonized by Lactobacillus F19 2 weeks after consumption, and two elderly subjects remained colonized after 8 weeks (12, 13) . This shows that Lactobacillus F19 can colonize the intestinal tract of some individuals for relatively long periods following the cessation of probiotic intake.
Adhesion to the intestinal mucosa is considered a desirable characteristic for potential probiotic bacteria, possibly aiding colonization and probiotic action including immunomodulation (14, 15) . In Trial B, samples that represented the colonic lumen (faecal) and the colonic mucosa (biopsy) were collected in order to determine the intestinal location of the bacteria. Biopsy samples were washed prior to microbiological analysis so that only bacteria adhering to the mucosa were enumerated. Although in ×itro studies using mucus from the intestinal mucosa have indicated that adhesion to intestinal mucus by Lactobacillus F19 was moderate to poor compared with other intestinal bacteria tested (16, 17) , the results of Trial B (Table II) indicate that Lactobacillus F19 was both in the lumen and adhering to the mucosa of the colon following consumption. In contrast to most faecal samples, Lactobacillus F19 only dominated the Lactobacillus community on the mucosa in two of ve volunteers. This may re ect colonization resistance by the indigenous mucosal microbiota of some individuals, or may be the normal distribution of Lactobacillus F19 within its niché in the colon. Mucosal biopsies taken from the ascending, transverse, and descending colon contained similar levels of Lactobacillus F19 (data not shown), demonstrating that it can colonize the length of the colon.
Trials involving adhesive and non-adhesive isogenic mutants of Lactobacillus crispatus showed that after ingestion by humans, the adhesive strain colonized the intestinal mucosa (biopsy samples) and persisted longer in the intestinal tract (18) . The ability of Lactobacillus F19 to adhere to intestinal mucosa may provide it too with an advantage in colonizing the human intestinal tract.
Effects on other intestinal bacteria
One of the proposed bene ts of probiotics is to prevent overgrowth or colonization by deleterious microorganisms within the intestinal tract following perturbations to the microbial ecosystem. It follows that it is undesirable for an exogenous probiotic to disturb the microbial balance in the intestinal tract of healthy individuals. Techniques such as PCR using universal bacterial primers, coupled with denaturing gradient gel electrophoresis (DGGE), allow visualization of the major groups of bacteria within the intestinal microbiota (19) . Samples from Trial A ( ve from different individuals in the placebo group and ve from the treatment group) were analysed before and after feeding. The subjects were young children, an age group for whom it is known that the composition of the intestinal microbiota is still developing and is relatively unstable (20) . Some changes were observed in the microbiota composition in the individuals tested in Trial A (Fig. 1) . However, none correlated with the consumption of Lactobacillus F19, indicating that this probiotic does not disturb the balance of major population groups within the intestinal microbiota. A band for Lactobacillus F19 was not visible on the gel suggesting that, while Lactobacillus F19 dominated the luminal Lactobacillus population during treatment, it constituted less than 1% of the total bacterial population in the intestinal tract. Recently, speci c PCR-DGGE has been developed for intestinal bi dobacteria and the Lactobacillus group (21, 22) . Analysis of the speci c Lactobacillus population in faecal samples of children indicated that it is rather unstable, like the dominant community (22) . Furthermore, using this approach the Lactobacillus F19 strain was detected throughout the feeding period of children (Trial A), and again provided support for the natural presence of the Lactobacillus F19 strain within the intestinal community.
SAFETY OF Lactobacillus F19
Included in each of the trials were observations monitoring of potential side-effects of probiotic consumption. These included intestinal discomfort, increased atulence, and changes in stool consistency and frequency. The trials included healthy subjects, adults with veri ed milk-hypersensitivity, and elderly people infected with Helicobacter pylori. No adverse effects of probiotic administration were observed in any of the pilot studies. The probiotic was well tolerated by all individuals (a total of 85 subjects consumed the probiotic) including those in Trial D, in which the probiotic was consumed daily for 3 months without adverse effects. The fact that no side-effects were detected in subjects ranging in age from 1 to \ 85 years, and in healthy individuals and subjects suffering mild illnesses (milk-hypersensitivity and H. pylori infection) suggests that Lactobacillus F19 is a safe microbial food supplement. Adding weight to this argument are the strain's origin from the intestinal tract of a healthy human and its natural prevalence in a healthy human population.
CONCLUSIONS
Lactobacillus F19 is an emerging probiotic with good technological characteristics. It now has a proven ability to survive gastric transit and to persist in the colonic environment of humans. This was achieved in subjects over a wide range of ages from the very young (1 year) to the very old (\ 85 years), and with four different food delivery matrices. It appears that Lactobacillus F19 is indigenous to the intestinal tract of a portion of the population in Finland in Sweden. This, combined with the absence of deleterious effects during the human feeding trials, even in subjects with underlying disorders, suggests that the strain is safe for use as a human probiotic. The way forward is open for further clinical testing of this strain to assess its ef cacy in contributing to improved human health. As for all probiotics, identifying health bene ts stemming from ingestion of Lactobacillus F19 against speci c intestinal disorders, and determining their mechanisms of action are the pending research challenges.
